Literature DB >> 29270052

The OncoSim model: development and use for better decision-making in Canadian cancer control.

C L Gauvreau1, N R Fitzgerald1, S Memon1, W M Flanagan2, C Nadeau2, K Asakawa2, R Garner2, A B Miller3, W K Evans4, C M Popadiuk5, M Wolfson6, A J Coldman7.   

Abstract

The Canadian Partnership Against Cancer was created in 2007 by the federal government to accelerate cancer control across Canada. Its OncoSim microsimulation model platform, which consists of a suite of specific cancer models, was conceived as a tool to augment conventional resources for population-level policy- and decision-making. The Canadian Partnership Against Cancer manages the OncoSim program, with funding from Health Canada and model development by Statistics Canada. Microsimulation modelling allows for the detailed capture of population heterogeneity and health and demographic history over time. Extensive data from multiple Canadian sources were used as inputs or to validate the model. OncoSim has been validated through expert consultation; assessments of face validity, internal validity, and external validity; and model fit against observed data. The platform comprises three in-depth cancer models (lung, colorectal, cervical), with another in-depth model (breast) and a generalized model (25 cancers) being in development. Unique among models of its class, OncoSim is available online for public sector use free of charge. Users can customize input values and output display, and extensive user support is provided. OncoSim has been used to support decision-making at the national and jurisdictional levels. Although simulation studies are generally not included in hierarchies of evidence, they are integral to informing cancer control policy when clinical studies are not feasible. OncoSim can evaluate complex intervention scenarios for multiple cancers. Canadian decision-makers thus have a powerful tool to assess the costs, benefits, cost-effectiveness, and budgetary effects of cancer control interventions when faced with difficult choices for improvements in population health and resource allocation.

Entities:  

Keywords:  OncoSim; cancer control; cancer modelling; cancer outcome projections; cancer system resource allocation

Year:  2017        PMID: 29270052      PMCID: PMC5736482          DOI: 10.3747/co.24.3850

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  13 in total

1.  Modeling for health care and other policy decisions: uses, roles, and validity.

Authors:  M C Weinstein; E L Toy; E A Sandberg; P J Neumann; J S Evans; K M Kuntz; J D Graham; J K Hammitt
Journal:  Value Health       Date:  2001 Sep-Oct       Impact factor: 5.725

2.  Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I non-small cell lung cancer in Canada.

Authors:  Alexander V Louie; George B Rodrigues; David A Palma; Suresh Senan
Journal:  Oncologist       Date:  2014-06-20

3.  Performance of the cancer risk management model lung cancer screening module.

Authors:  William M Flanagan; William K Evans; Natalie R Fitzgerald; John R Goffin; Anthony B Miller; Michael C Wolfson
Journal:  Health Rep       Date:  2015-05       Impact factor: 4.796

4.  Recommendations on screening for colorectal cancer in primary care.

Authors: 
Journal:  CMAJ       Date:  2016-02-22       Impact factor: 8.262

Review 5.  Recommendations on screening for lung cancer.

Authors: 
Journal:  CMAJ       Date:  2016-03-07       Impact factor: 8.262

6.  The levels of evidence and their role in evidence-based medicine.

Authors:  Patricia B Burns; Rod J Rohrich; Kevin C Chung
Journal:  Plast Reconstr Surg       Date:  2011-07       Impact factor: 4.730

7.  Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness.

Authors:  John R Goffin; William M Flanagan; Anthony B Miller; Natalie R Fitzgerald; Saima Memon; Michael C Wolfson; William K Evans
Journal:  Lung Cancer       Date:  2016-09-28       Impact factor: 5.705

8.  Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada.

Authors:  C Popadiuk; C L Gauvreau; M Bhavsar; C Nadeau; K Asakawa; W M Flanagan; M C Wolfson; A J Coldman; S Memon; N Fitzgerald; J Lacombe; A B Miller
Journal:  Curr Oncol       Date:  2016-02-29       Impact factor: 3.677

9.  Validation of Models Used to Inform Colorectal Cancer Screening Guidelines: Accuracy and Implications.

Authors:  Carolyn M Rutter; Amy B Knudsen; Tracey L Marsh; V Paul Doria-Rose; Eric Johnson; Chester Pabiniak; Karen M Kuntz; Marjolein van Ballegooijen; Ann G Zauber; Iris Lansdorp-Vogelaar
Journal:  Med Decis Making       Date:  2016-01-08       Impact factor: 2.583

10.  Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force.

Authors:  Harry J de Koning; Rafael Meza; Sylvia K Plevritis; Kevin ten Haaf; Vidit N Munshi; Jihyoun Jeon; Saadet Ayca Erdogan; Chung Yin Kong; Summer S Han; Joost van Rosmalen; Sung Eun Choi; Paul F Pinsky; Amy Berrington de Gonzalez; Christine D Berg; William C Black; Martin C Tammemägi; William D Hazelton; Eric J Feuer; Pamela M McMahon
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

View more
  11 in total

Review 1.  This is a call to oncologists for action.

Authors:  C Micó; A Berrocal; A Blasco; C Caballero; V Iranzo; M Lobo; C Camps
Journal:  Clin Transl Oncol       Date:  2018-05-23       Impact factor: 3.405

2.  Evidence in medicine: math versus biology!

Authors:  T Younis; M Thana; C Skedgel
Journal:  Curr Oncol       Date:  2017-12-20       Impact factor: 3.677

3.  Moving toward the elimination of cervical cancer: modelling the health and economic benefits of increasing uptake of human papillomavirus vaccines.

Authors:  A Smith; N Baines; S Memon; N Fitzgerald; J Chadder; C Politis; E Nicholson; C Earle; H Bryant
Journal:  Curr Oncol       Date:  2019-04-01       Impact factor: 3.677

4.  Projected Impact of Weight Gain During the COVID-19 Pandemic on the Future Burden of Cancer in Canada.

Authors:  Rachel A Murphy; Jaclyn Parks; Ryan Woods; Darren R Brenner; Yibing Ruan; Parveen Bhatti
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

5.  Estimating the future cancer management costs attributable to modifiable risk factors in Canada.

Authors:  Yibing Ruan; Abbey E Poirier; Joy Pader; Keiko Asakawa; Chaohui Lu; Saima Memon; Anthony B Miller; Stephen D Walter; Paul J Villeneuve; Will D King; Karena D Volesky; Leah Smith; Prithwish De; Christine M Friedenreich; Darren R Brenner
Journal:  Can J Public Health       Date:  2021-05-25

6.  Predicting the Epidemiological Dynamics of Lung Cancer in Japan.

Authors:  Takayuki Yamaguchi; Hiroshi Nishiura
Journal:  J Clin Med       Date:  2019-03-08       Impact factor: 4.241

7.  Use of Simulation Modeling to Inform Decision Making for Health Care Systems and Policy in Colorectal Cancer Screening: Protocol for a Systematic Review.

Authors:  Heather Smith; Peyman Varshoei; Robin Boushey; Craig Kuziemsky
Journal:  JMIR Res Protoc       Date:  2020-05-13

8.  The Value of All-Cause Mortality as a Metric for Assessing Breast Cancer Screening.

Authors:  Martin J Yaffe; James G Mainprize
Journal:  J Natl Cancer Inst       Date:  2020-10-01       Impact factor: 13.506

9.  The EU-TOPIA evaluation tool: An online modelling-based tool for informing breast, cervical, and colorectal cancer screening decisions in Europe.

Authors:  Andrea Gini; Nicolien T van Ravesteyn; Erik E L Jansen; Eveline A M Heijnsdijk; Carlo Senore; Ahti Anttila; Dominika Novak Mlakar; Piret Veerus; Marcell Csanádi; Nadine Zielonke; Sirpa Heinävaara; György Széles; Nereo Segnan; Harry J de Koning; Iris Lansdorp-Vogelaar
Journal:  Prev Med Rep       Date:  2021-04-30

10.  Simulation modeling validity and utility in colorectal cancer screening delivery: A systematic review.

Authors:  Heather Smith; Peyman Varshoei; Robin Boushey; Craig Kuziemsky
Journal:  J Am Med Inform Assoc       Date:  2020-06-01       Impact factor: 4.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.